Comparación de la flebotomía con eritrocitaféresis en la sobrecarga de hierro en portadores de mutaciones del gen HFE

Fernández‐Mosteirín, Nuria; Salvador-Osuna, Carlos; García-Erce, José Antonio; Orna, Elisa; Pérez-Lungmus, Gonzalo; Giralt, Manuel

doi:10.1157/13092766

Cited by 21 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This method has been evaluated in 1 randomized 1 and a few nonrandomized studies. 2,3 Results from all show that erythrocytapheresis is a much more effective and faster method and removes at least twice as much iron per single procedure compared with phlebotomy. This is especially advantageous in situations of life-threatening organ complications because of iron overload as in this case.…”

Section: Discussionmentioning

confidence: 99%

End-Stage Cardiomyopathy Because of Hereditary Hemochromatosis Successfully Treated With Erythrocytapheresis in Combination With Left Ventricular Assist Device Support

Rombout‐Sestrienkova

Jonge

Martinakova

et al. 2014

Circ: Heart Failure

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

End-Stage Cardiomyopathy Because of Hereditary Hemochromatosis Successfully Treated With Erythrocytapheresis in Combination With Left Ventricular Assist Device Support

Rombout‐Sestrienkova

Jonge

Martinakova

et al. 2014

Circ: Heart Failure

View full text Add to dashboard Cite

“…Erythrocytapheresis of 350-800 ml of RBCs over several weeks is comparable with phlebotomy in adverse events and treatment costs [156,157]. The reduction in the number of required procedures per year to maintain a goal ferritin level may give a cost benefit of erythrocytapheresis over phlebotomy [158]. Erythrocytapheresis is a modality which has proven to reduce treatment duration of patients with iron overload from HH [159].…”

Section: Hereditary Hemochromatosis (Hh)mentioning

confidence: 99%

Therapeutic Apheresis and Human Monoclonal Antibodies in Non-Immunologic Diseases. TA, HMA in non-immunologic diseases

2023

JCEI

View full text Add to dashboard Cite

Non-immunologic diseases such as nephrological, blood diseases, dyslipoproteinemia, cancer, infections, intoxications etc. have often a severe course or a bad prognosis. Since more than 45 years, therapeutic apheresis has led in combination with other therapies to a steady increase in survival rates. Therapeutic apheresis is indicated in the most of the non-immunologic diseases, and in all antibody-mediated diseases. Since the introduction of hollow fiber membranes, a complete separation of the corpuscular components, pathologic substances, antibodies, toxins etc. is reached. The mortality rate of severe non-immunologic diseases is reduced by therapeutic apheresis. Other new therapies are various human monoclonal antibodies alone or in combination with therapeutic apheresis. The pathological aspects, the first-line and second-lines therapies for non-immunologic such as nephrological, neurological, gastroenterological, hematological diseases, and others are shown. The guidelines of the Apheresis Applications Committee of the American Society for Apheresis are cited. Therapeutic apheresis and/or human monoclonal antibodies have shown to effectively cure severe diseases without immunologic origin.

show abstract

Guidelines on the use of therapeutic apheresis in clinical practice—Evidence‐based approach from the apheresis applications committee of the American Society for Apheresis

Szczepiórkowski

Winters

Bandarenko

et al. 2010

J of Clinical Apheresis

499

285

View full text Add to dashboard Cite

The American Society for Apheresis (ASFA) Apheresis Applications Committee is charged with a review and categorization of indications for therapeutic apheresis. Beginning with the 2007 ASFA Special Issue (fourth edition), the subcommittee has incorporated systematic review and evidence-based approach in the grading and categorization of indications. This Fifth ASFA Special Issue has further improved the process of using evidence-based medicine in the recommendations by refining the category definitions and by adding a grade of recommendation based on widely accepted GRADE system. The concept of a fact sheet was introduced in the Fourth edition and is only slightly modified in this current edition. The fact sheet succinctly summarizes the evidence for the use of therapeutic apheresis. The article consists of 59 fact sheets devoted to each disease entity currently categorized by the ASFA as category I through III. Category IV indications are also listed.

show abstract

Comparación de la flebotomía con eritrocitaféresis en la sobrecarga de hierro en portadores de mutaciones del gen HFE

Cited by 21 publications

References 7 publications

End-Stage Cardiomyopathy Because of Hereditary Hemochromatosis Successfully Treated With Erythrocytapheresis in Combination With Left Ventricular Assist Device Support

End-Stage Cardiomyopathy Because of Hereditary Hemochromatosis Successfully Treated With Erythrocytapheresis in Combination With Left Ventricular Assist Device Support

Therapeutic Apheresis and Human Monoclonal Antibodies in Non-Immunologic Diseases. TA, HMA in non-immunologic diseases

Guidelines on the use of therapeutic apheresis in clinical practice—Evidence‐based approach from the apheresis applications committee of the American Society for Apheresis

Contact Info

Product

Resources

About